November 10, 2026 — The U.S. Food and Drug Administration (FDA) announced that it is requiring updated safety warnings for GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, due to a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss.
The FDA is requiring manufacturers to add information about this potential risk to the Warnings and Precautions section of GLP-1 drug labels.
The FDA’s decision follows a comprehensive safety investigation prompted in part by a 2024 study examining the potential link between semaglutide and NAION. As part of its investigation, the agency analyzed data from 126 clinical trials, finding 6.4 NAION cases per 100,000 person-years among GLP-1 users compared with 3.8 cases among patients receiving a placebo or other non-GLP-1 diabetes medications. The FDA also reviewed adverse event reports, existing animal data, and published observational studies, and conducted a separate study using real-world patient data.
Based on the collective evidence, the FDA concluded that GLP-1 medications may increase the risk of NAION and that updated safety warnings were warranted.
NAION occurs when blood flow to the optic nerve is reduced, potentially causing sudden, painless vision loss, blurred vision, blind spots, or other visual disturbances. The FDA advises patients experiencing these symptoms to seek immediate medical attention.
About The Lanier Law Firm's Efforts to Seek Justice for Victims of GLP-1 Drugs and NAION
For more than 35 years, The Lanier Law Firm has fought for individuals and families harmed by dangerous drugs and pharmaceutical products, securing millions of dollars in settlements and verdicts against major corporations.
The firm is actively involved in litigation involving Ozempic and other GLP-1 medications and their alleged connection to NAION and serious vision loss. In June 2026, Senior Attorney David Rosenband was appointed to the Plaintiffs’ Executive Committee in the New Jersey GLP-1/NAION multicounty litigation, helping guide legal proceedings on behalf of individuals pursuing claims for alleged vision injuries.
If you or a loved one has been diagnosed with NAION after using semaglutide, tirzepatide, liraglutide, or other GLP-1 receptor agonists, you may be eligible to pursue legal action. Contact The Lanier Law Firm at 800-723-3216 to discuss your case and explore your legal options.